TC BioPharm Regains Compliance With Nasdaq Minimum Bid Price Requirement
Portfolio Pulse from Benzinga Newsdesk
TC BioPharm (NASDAQ:TCBP), a clinical stage biotechnology company, has regained compliance with Nasdaq's minimum bid price requirement. The company's stock maintained a closing bid price of $1.00 or more for at least 10 consecutive business days, satisfying Nasdaq's condition for continued listing on the Nasdaq Capital Market. Previously, on June 22, 2023, TCBP was notified of non-compliance due to its stock price falling below the $1.00 threshold for 30 consecutive business days.
January 04, 2024 | 1:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TC BioPharm has regained compliance with Nasdaq's minimum bid price requirement, which is a positive development for the company and its investors.
Regaining compliance with Nasdaq's minimum bid price requirement is a significant positive development for TCBP. It removes the immediate risk of delisting, which can restore investor confidence and potentially improve stock liquidity and access to capital. The news is directly related to the company and is of high importance to investors as it affects the company's ability to remain listed on a major stock exchange.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100